TY - JOUR
T1 - The IPTA Nashville consensus conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children
T2 - II—consensus guidelines for prevention
AU - Green, Michael
AU - Squires, James E.
AU - Chinnock, Richard E.
AU - Comoli, Patrizia
AU - Danziger-Isakov, Lara
AU - Dulek, Daniel E.
AU - Esquivel, Carlos O.
AU - Höcker, Britta
AU - L'Huillier, Arnaud G.
AU - Mazariegos, George Vincent
AU - Visner, Gary A.
AU - Bollard, Catherine M.
AU - Dipchand, Anne I.
AU - Ferry, Judith A.
AU - Gross, Thomas G.
AU - Hayashi, Robert
AU - Maecker-Kolhoff, Britta
AU - Marks, Stephen
AU - Martinez, Olivia M.
AU - Metes, Diana M.
AU - Michaels, Marian G.
AU - Preiksaitis, Jutta
AU - Smets, Françoise
AU - Swerdlow, Stephen H.
AU - Trappe, Ralf U.
AU - Wilkinson, James D.
AU - Allen, Upton
AU - Webber, Steven A.
AU - Dharnidharka, Vikas R.
N1 - Funding Information:
C.M.B. is on the scientific advisory boards for Catamaran Bio and Mana Therapeutics with stock options and/or ownership is on the Board of Directors for Caballeta Bio with stock options and has stock in Neximmune and Torque Therapeutics. C.M.B has patent applications related to EBV‐specific T cells licensed to Cellmedica, has served on ad hoc advisory boards for BMS, Pfizer, Roche, and CDR‐Life AG, and serves on the DSMB for SOBI. VD is a consultant to ATARA. PC is a consultant for ATARA. MG is a consultant to Allovir. OMM was a consultant to ATARA. RUT received grant support, personal fees, and other nonfinancial support from Roche and ATARA. SAW is on a Scientific Advisory Board for Cellevolve. The following authors have no relevant conflicts to declare: UA, REC, AD, DED, COE, JAF, TGG, BH, RH, LDI, AGL, BMK, DMM, GVM, MGM, SM, JP, FS, SHS, GV, and JDW.
Funding Information:
The methods for the development of these consensus guidelines are described in detail in the accompanying article. In brief, the International Pediatric Transplant Association Consensus Conference on PTLD after Pediatric Solid Organ Transplantation took place in Nashville, Tennessee on March 12–13, 2019, and the work of conference members continued until the end of December 2021. The goal was to produce evidence‐based consensus guidelines on the definitions, prevention, and management of PTLD and related disorders based on the critical review of the literature and consensus of experts. The consensus conference was comprised of 29 international experts in organ transplantation and PTLD from the fields of hepatology, nephrology, cardiology, pulmonology, infectious diseases, immunology, hematology‐oncology, surgery, virology, immunology, pathology, and epidemiology. The Working Group was supported by experts in systematic reviews from the Vanderbilt University Medical Center's Center for Knowledge Management ( https://ckm.vumc.org/ckm/ ). 1
Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022
Y1 - 2022
N2 - The International Pediatric Transplant Association (IPTA) convened an expert consensus conference to assess current evidence and develop recommendations for various aspects of care relating to post-transplant lymphoproliferative disorder after solid organ transplantation in children. In this report from the Prevention Working Group, we reviewed the existing literature regarding immunoprophylaxis and chemoprophylaxis, and pre-emptive strategies. While the group made a strong recommendation for pre-emptive reduction of immunosuppression at the time of EBV DNAemia (low to moderate evidence), no recommendations for use could be made for any prophylactic strategy or alternate pre-emptive strategy, largely due to insufficient or conflicting evidence. Current gaps and future research priorities are highlighted.
AB - The International Pediatric Transplant Association (IPTA) convened an expert consensus conference to assess current evidence and develop recommendations for various aspects of care relating to post-transplant lymphoproliferative disorder after solid organ transplantation in children. In this report from the Prevention Working Group, we reviewed the existing literature regarding immunoprophylaxis and chemoprophylaxis, and pre-emptive strategies. While the group made a strong recommendation for pre-emptive reduction of immunosuppression at the time of EBV DNAemia (low to moderate evidence), no recommendations for use could be made for any prophylactic strategy or alternate pre-emptive strategy, largely due to insufficient or conflicting evidence. Current gaps and future research priorities are highlighted.
UR - http://www.scopus.com/inward/record.url?scp=85142101299&partnerID=8YFLogxK
U2 - 10.1111/petr.14350
DO - 10.1111/petr.14350
M3 - Review article
C2 - 36369745
AN - SCOPUS:85142101299
SN - 1397-3142
JO - Pediatric transplantation
JF - Pediatric transplantation
ER -